Literature DB >> 8727140

Prognostic significance of type 1 neurofibromatosis (von Recklinghausen Disease) in childhood optic glioma.

A V Deliganis1, J R Geyer, M S Berger.   

Abstract

Although the association between optic glioma and neurofibromatosis is well recognized, few studies have systematically compared the outcomes of patients with optic gliomas and neurofibromatosis and patients with optic gliomas without neurofibromatosis. In the present study, patients with optic gliomas and Type 1 neurofibromatosis (NF-1) were compared with patients with optic gliomas without NF-1, with respect to survival, time to tumor progression, and tumor location. Forty-four patients with optic gliomas who were evaluated between 1949 and 1991 were studied retrospectively. Sixteen of 44 patients (36%) met the National Institutes of Health criteria for NF-1. The medical records of all patients were examined, and letters of inquiry were sent to every living patient to ascertain current health statuses. Death certificates were obtained to determine causes of death. Follow-up averaged 7.2 years (10.2 yr for patients with NF-1, 5.4 yr for patients without NF-1). The 5- and 10-year survival rates for patients with optic gliomas and NF-1 were 93 and 81%, respectively. For those patients with optic gliomas who did not have NF-1, 5- and 10-year survival rates were 83 and 76%, respectively. Seventeen patients experienced tumor progression (5 with NF-1, 12 without NF-1). A difference was observed in the mean time to tumor progression (first relapse) between the two groups (mean time with NF-1, 8.37 yr; without NF-1, 2.39 yr [P < 0.01]). However, no significant difference in overall survival, as evaluated by a log-rank test of the respective Kaplan-Meier survival curves, was observed between the two groups. A significant difference in distribution of tumor location between the group with NF-1 and the group without NF-1 was also noted (Fisher's exact test, P = 0.0338), although the number of patients evaluated in this series was too small to determine whether this difference in tumor location influenced relapse rate. We conclude that optic gliomas in patients with neurofibromatosis have a different distribution of location as opposed to those in patients without neurofibromatosis, and, for first relapse, the presence of neurofibromatosis is a significant favorable factor.

Entities:  

Mesh:

Year:  1996        PMID: 8727140     DOI: 10.1097/00006123-199606000-00010

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  18 in total

1.  Optic pathway glioma: correlation of imaging findings with the presence of neurofibromatosis.

Authors:  L Kornreich; S Blaser; M Schwarz; A Shuper; T H Vishne; I J Cohen; R Faingold; S Michovitz; B Koplewitz; G Horev
Journal:  AJNR Am J Neuroradiol       Date:  2001 Nov-Dec       Impact factor: 3.825

Review 2.  [Orbital tumors].

Authors:  P Papanagiotou; I Q Grunwald; M Politi; C Roth; H Körner; W Reith
Journal:  Radiologe       Date:  2008-12       Impact factor: 0.635

Review 3.  Pediatric low-grade gliomas.

Authors:  Angela J Sievert; Michael J Fisher
Journal:  J Child Neurol       Date:  2009-11       Impact factor: 1.987

Review 4.  Neoplasms associated with germline and somatic NF1 gene mutations.

Authors:  Sachin Patil; Ronald S Chamberlain
Journal:  Oncologist       Date:  2012-01-12

5.  Proliferative activity as measured by MIB-1 labeling index and long-term outcome of visual pathway astrocytomas in children.

Authors:  T Czech; I Slavc; M Aichholzer; C Haberler; W Dietrich; K Dieckmann; W Koos; H Budka
Journal:  J Neurooncol       Date:  1999-04       Impact factor: 4.130

Review 6.  Visual function tests including the role of optical coherence tomography in neurofibromatosis 1.

Authors:  Daphna Mezad-Koursh; Anat Bachar Zipori; Dinah Zur; Lior Degabli; Meital Ben-Dov; Ainat Klein
Journal:  Childs Nerv Syst       Date:  2020-08-04       Impact factor: 1.475

Review 7.  Update on the management of familial central nervous system tumor syndromes.

Authors:  Andreas F Hottinger; Yasmin Khakoo
Journal:  Curr Neurol Neurosci Rep       Date:  2007-05       Impact factor: 5.081

8.  Responsiveness of progressive optic pathway tumors to cisplatin-based chemotherapy in children.

Authors:  Ting-Rong Hsu; Tai-Tong Wong; Feng-Chi Chang; Donald M Ho; Ren-Bin Tang; Peck-Foong Thien; Kai-Ping Chang
Journal:  Childs Nerv Syst       Date:  2008-09-04       Impact factor: 1.475

9.  Rapid development of optic glioma in a patient with hybrid phakomatosis: neurofibromatosis type 1 and tuberous sclerosis.

Authors:  Sami H Erbay; Stephen A Oljeski; Rafeeque Bhadelia
Journal:  AJNR Am J Neuroradiol       Date:  2004-01       Impact factor: 3.825

10.  Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era.

Authors:  C Cappelli; J Grill; M Raquin; A Pierre-Kahn; A Lellouch-Tubiana; M J Terrier-Lacombe; J L Habrand; D Couanet; R Brauner; D Rodriguez; O Hartmann; C Kalifa
Journal:  Arch Dis Child       Date:  1998-10       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.